Start here if you're new
what it is
Solventum makes hospital supplies, dental gear, billing software, and filtration products for healthcare providers.
how it gets paid
Last year Solventum made $8.3B in revenue. Medical Surgical was the main engine at $4.6B, or 56% of sales.
why it's growing
Revenue grew 0.9% last year. Solventum made an upfront cash payment of $725 million and has agreed to pay up to $125 million in contingent payments based on the achievement.
what just happened
Solventum beat by $0.05 a share, with $1.57 versus $1.52 expected.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
13.1x trailing p/e — the market's not buying it — or you found a deal
15.0% return on capital — nothing to write home about
$6.60 fy2027 eps est
$10B fy2029 rev est
xvary composite: 60/100 — average
What they do
Solventum makes hospital supplies, dental gear, billing software, and filtration products for healthcare providers.
MedSurg is 56% of sales, so one big business pays the bills. The rest is split across dental, software, and filters, which keeps hospitals tied to your system. Leaving means retraining staff and reworking billing across 22,000 employees.
How they make money
$8.3B
annual revenue · their business grew +0.9% last year
Medical Surgical
$4.6B
+2.1%
Dental Solutions
$1.3B
+8.4%
Health Information Systems
$1.3B
+5.9%
Purification & Filtration
$1.0B
+0.0%
The products that matter
medical and surgical supplies
MedSurg
$4.6B · largest disclosed segment
This is the biggest disclosed segment at $4.6B, and it helped drive 3.5% organic sales growth on the $2.0B quarter. If this slows, the whole story slows with it.
growth driver
sterilization and safety products
Infection Prevention
$3.7B · growth went negative
This business contributes $3.7B in disclosed revenue, but growth fell 2.1%. You do not need it to be explosive. You do need it to stop shrinking.
stability test
Key numbers
13.1x
trailing P/E
Price-to-earnings means price divided by profit. At 13.1x, you pay $13.10 for each $1 of trailing earnings.
22.0%
operating margin
Operating margin means profit after running the business. At 22.0%, the company keeps 22 cents of every revenue dollar.
$5.1B
long-term debt
Debt means money owed later. At $5.1B, leverage leaves less room for mistakes.
15.0%
return on capital
Return on capital means profit from each dollar invested. At 15.0%, management still earns more than many businesses.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- long-term debt $5.1B (27% of capital)
- net profit margin 13.4% — keeps 13 cents of every dollar in revenue
- return on equity 24% — $0.24 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for SOLV right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Solventum beat by $0.05 a share, with $1.57 versus $1.52 expected.
Revenue was $6.3B and gross margin was 54.1%. The beat was small, but it came with a margin number that still looks healthy by healthcare standards.
$6.3B
revenue
$1.57
eps
54.1%
gross margin
gross margin
Gross margin at 54.1% mattered most. On $6.3B revenue, every 1 point is about $63M.
-
solventum likely posted ongoing moderate top-line improvement for its fourth quarter ended december 31st. (results are due shortly after this report goes to press.) our forecast of $2.173 billion represents an approximate 4.8% increase over the prior-year period tally, with modest sales gains likely across all three of its business segments (medsurg, dental solutions, and health information systems).
-
following a september interim in which the three segments grew organically by 2.1%, 8.4%, and 5.9%, respectively, solventum has now demonstrated six consecutive quarters of volume growth following its spin-off from 3M Company. The company has announced its four-year ``transform for the future'' initiative.the program is designed to further accelerate solventum's profitable growth while strengthening its position in a rapidly changing healthcare environment. the initiative will reshape solventum's cost structure and improve operational efficiency while fueling innovation as the company shifts resources to its most attractive markets. once fully implemented, leadership targets approximately $500 million in annual cost savings, with a portion of it to be reinvested in strategic growth initiatives. solventum has acquired acera surgical, a private bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care.
-
the addition of acera's synthetic tissue matrix technology complements solventum's existing advanced wound care portfolio, enhancing the solutions its specialized commercial team can provide to clinicians in acute care settings.solventum made an upfront cash payment of $725 million and has agreed to pay up to $125 million in contingent payments based on the achievement of future milestones. Owing to its short trading history, solventum stock remains unranked for timeliness.
-
nonetheless, our estimates call for steady top-and bottom-line gains in both 2026 and 2027.
-
solventum stock has gained approximately 10% in value since our november review, yet still offers good appreciation potential out to 2029-2031 from the recent quotation.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is post-spin margin erosion in MedSurg and Infection Prevention.
med
Gross margin is moving the wrong way
Gross margin fell 270 basis points to 53.5%. For a business leaning on premium medical products, that is not background noise.
If that compression sticks, the market will keep treating 9.4x forward earnings as a warning, not a bargain.
med
The standalone story is still very young
Solventum has been independent from 3M only since April 2024. Shared systems, overhead resets, and operating discipline all matter more when the training wheels just came off.
If execution wobbles, the low multiple can stay low for longer than value investors want.
med
One disclosed segment is shrinking
Infection Prevention declined 2.1% while MedSurg grew 3.5%. That split matters because a two-engine business only feels durable when both engines work.
If the weak segment keeps slipping, organic growth can flatten even before any broader healthcare slowdown shows up.
med
Legal and regulatory proceedings are not a footnote
The company discloses numerous claims, lawsuits, and regulatory proceedings worldwide in its 10-Q. That is normal language until it becomes expensive language.
Any material settlement or operating restriction would hit a business doing roughly $10B in annual revenue and already working through a spin-off transition.
A company with roughly $10B in revenue can absorb noise. It cannot absorb repeated margin erosion while proving it deserves a medtech multiple.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
Gross margin stabilization
53.5% is still a strong number. The problem is the direction. If that 270-basis-point decline stops getting worse, the valuation debate changes fast.
calendar
Buyback deployment in 2026
A $1B authorization sounds bold. The pace matters more than the press release. Watch how much stock actually disappears.
trend
Infection Prevention growth
This segment fell 2.1%. A move back toward flat or better would make the revenue mix look far less fragile.
risk
Standalone execution under debt and legal overhang
With $5.1B in long-term debt and ongoing legal proceedings, this is not a spin-off that gets infinite time to figure itself out.
Analyst rankings
risk profile
average
Stability score 3 means this sits around the middle of the pack on risk. In human-speak, analysts do not see SOLV as especially safe or especially chaotic.
valuation setup
discounted
A 9.4x forward p/e says the stock is priced below what you usually see in medtech. The market is giving you a discount because it wants more proof.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 327 buyers vs. 342 sellers in 3q2025. total institutional holdings: 0.1B shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$47
$96
$79
current price
$72
target midpoint · 9% from current · 3-5yr high: $150 (+90% · 17% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive